Results 121 to 130 of about 71,529 (343)
The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5‐HT release in the frontal cortex of freely‐moving rats [PDF]
, 1993 Celine H.K. Cheng +3 more
openalex +1 more source
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
British Journal of Pharmacology, EarlyView.Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Binge drinking is a risky pattern of alcohol intake and a major predictor of alcohol use disorder (AUD). Current AUD medications have limited efficacy and poor patient compliance, calling for more effective therapeutics.
Connie J. Badolato +4 more
wiley +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology, EarlyView.Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
Biological Reviews, EarlyView.ABSTRACT Antipsychotic drugs (APDs) are a diverse class of neuroactive pharmaceuticals increasingly detected in surface and ground waters globally. Some APDs are classified as posing a high environmental risk, due, in part, to their tendency to bioaccumulate in wildlife, including fish.
Gabrielle Wasser‐Bennett +4 more
wiley +1 more source
Probiotics as technological innovations in psychiatric disorders: patents and research reviews
Frontiers in NutritionProbiotics have shown promising results in treating anxiety and depression by modulating the gut-brain-microbiota axis using probiotics, which has motivated increasing commercial and academic interest in innovations and the probiotic market.
Alyne Almeida de Lima +6 more
doaj +1 more source
Pharmacologic Characterization of a Novel Non-Benzodiazepine Selective Anxiolytic, DN-2327
, 1989 Takeo Wada +7 more
openalex +1 more source
Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics [PDF]
, 1995 Klaus A. Miczek +3 more
openalex +1 more source
Community Dentistry and Oral Epidemiology, EarlyView.ABSTRACT Objectives To develop the International Association for Disability and Oral Health Universal Case Mix Tool (iADH UCMT) that rates case complexity in the delivery of oral healthcare. Methods A modified e‐Delphi survey sought consensus on the content of a universal Case Mix Tool to rate the degree of adaptation over and above that required for ...
Caoimhin Mac Giolla Phadraig +4 more
wiley +1 more source